Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 4 from your keywords: author=McKeage K
cover
Docetaxel: A Review of its Use for the First-Line Treatment of Advanced Cast…
Comment Share
McKeage K

Docetaxel (Taxotere) is a well established anti-mitotic chemotherapy agent. Among other therapeutic indications, docetaxel plus prednisone is indicated for first-line chemotherapy in patients with castration-resistant prostate cancer (CRPC)

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fenofibrate: A Review of its Use in Dyslipidaemia
Comment Share
McKeage K

Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-a. Fenofibrate also has nonlipid, pleiotropic effects (e.g. reducing levels of fibrin…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Salmeterol/Fluticasone Propionate A Review of its Use in Asthma
Comment Share
McKeage K

Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting b2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and as…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fondaparinux: A Pharmacoeconomic Review of its Use in the Management of Non-…
Comment Share
McKeage K

In OASIS-5, a large pivotal trial in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), subcutaneous fondaparinux 2.5 mg once daily was noninferior to subcutaneous enoxaparin 1mg/kg twice daily (both agents were administered over a mean of about 5 days in combination with antiplatelet therapy) in reducing death or ischaemic events at 9 days, and the efficacy was maintain…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-